Form 8-K - Current report:
SEC Accession No. 0001193125-25-157390
Filing Date
2025-07-10
Accepted
2025-07-10 08:00:17
Documents
17
Period of Report
2025-07-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d92808d8k.htm   iXBRL 8-K 32157
2 EX-1.1 d92808dex11.htm EX-1.1 177532
3 EX-5.1 d92808dex51.htm EX-5.1 7792
4 EX-99.1 d92808dex991.htm EX-99.1 21183
8 GRAPHIC g92808g0709130424983.jpg GRAPHIC 2577
9 GRAPHIC g92808g92p61.jpg GRAPHIC 3954
  Complete submission text file 0001193125-25-157390.txt   424246

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA cogt-20250707.xsd EX-101.SCH 2856
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE cogt-20250707_lab.xml EX-101.LAB 17994
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cogt-20250707_pre.xml EX-101.PRE 11265
19 EXTRACTED XBRL INSTANCE DOCUMENT d92808d8k_htm.xml XML 3625
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

EIN.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 251114855
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)